Academic Program

Program

Thursday, October 27, 2022

[8:00-9:15] Session I:  WM Predisposition

Mary McMaster, Alessandra Trojani [Chairs]

GWAS Study Findings in Familial Plasma Cell Dyscrasias incl. WM

Mary McMaster, National Institutes of Health, USA

Clonal Lymphopoiesis and predisposition to WM

Bruno Paiva, University of Navarra, Spain

Transcriptional differences between IGM MGUS and WM

Alessandra Trojani, Ospedale Metropolitano Niguarda, Italy

Twin Genomic Studies in WM: Identification of FHL2 Gene Mutation

Jian Hou, Renji Hospital, Shanghai Jiao Tong University, China

Clonal Hematopoiesis and risk of WM Progression

Adam Sperling, Dana Farber Cancer Institute, USA

 

[9:15-10:45] Session II: WM Genomics I

Bruno Paiva, Zachary Hunter [Chairs]

Comprehensive WES Study of WM-300 project

Zachary Hunter, Dana Farber Cancer Institute, USA

Genomic differences of CXCR4 wild-type and mutated clones

Cristina Jimenez, University of Salamanca, Spain

Integration of cytogenetic and molecular screening for first line patients

Damien Roos-Weil, Hôpital Pitié-Salpêtrière, France

Genomic Variants in Chinese Patients with WM

Shuhua Yi, Tianjin Medical Center, China

Lon Non-Coding RNA Expression in IGM MGUS and WM

Jonas Paludo, Mayo Clinic, USA

Single Cell Analysis of MYD88 mutated and wild-type WM

Tina Bagratuni, University of Athens, Greece

 

[10:45-11:15] Morning Break

 

[11:15-13:00] Session III: WM Genomics II

Marzia Varettoni, Nikhil Munshi [Chairs]

DNA Methylation Profiling in WM

Damien Roos-Weil, Hôpital Pitié-Salpêtrière, France

Epigenomic Regulation by ATAC Seq

Zachary Hunter, Dana Farber Cancer Institute, USA

Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in WM and in IgM-MGUS (FIL_BIOWM)

Marzia Varettoni, University of Pavia, Italy

Distinct Genomic Profile Characterizes IGM MM from WM

Nikhil Munshi, Dana Farber Cancer Institute, USA

Genomic Variants in Non-MYD88 mutated WM

Zachary Hunter, Dana Farber Cancer Institute, USA

Genomic Landscape of WM reveals late developing CAN

Kylee MacLachlan, Memorial Sloan Kettering Cancer Center, USA

Proteomic and Metabolomic Studies in WM

Shahrzad Jalali, Mayo Clinic, USA

 

[13:00-14:00] LUNCH

 

[14:00-14:30] Keynote Lectures

What the genomics of WM tells us about its curability

Keynote Speaker: Steven Treon, Dana Farber Cancer Institute, USA

Targeting the Epigenome: Opportunities for WM

Keynote Speaker: Ari Melnick, Cornell University, USA

 

 

 

[14:30-16:00] Session IV: Transgenic Models for WM

Ruben Carrasco, Jose Martinez-Climent, [Chairs]

MYD88 Transgenic Model

Klaus Rajewsky, Max Delbrück Center for Molecular Medicine, Germany

MYD88 L265P Transgenic Model

Ruben Carrasco, Dana Farber Cancer Institute, USA

Unraveling and targeting the immune microenvironment in MYD88 lymphomas

Jose Martinez-Climent, University of Navarra, Spain

Continuous activation of mutated MYD88

Christelle Vincent-Fabert, UMR CNRS/INSERM, France

CXCR4 Transgenic Model

Karl Balabanian, Inserm Unité Mixte de Recherche S996, France

TBL1XR1 Transgenic Model

Ari Melnick, Cornell University, USA

 

[16:00-16:30] Afternoon Break

 

[16:30-17:45] Session V: Signalomics in WM

Irene Ghobrial, Aldo Roccaro [Chairs]

MYD88 driven HCK pro-survival signaling

Guang Yang, Dana Farber Cancer Institute, USA

Mutated MYD88 related Ubiquitination

Yong Li, Baylor College of Medicine, USA

ERK dysregulation mediated by aberrant WNK2 expression

Maria Luisa Guerrera, Dana Farber Cancer Institute, USA

FGF/FGF-R Axis in MYD88 Mutated WM

Aldo Roccaro, ASST Spedali Civili di Brescia, Italy

Genomic evolution of ibrutinib resistant clones

Cristina Jimenez, University of Salamanca, Spain

 

[18:30] Poster Presentations & Dinner Reception

Presentation of Young Investigator Awards

Presentation of Robert A. Kyle Award

Friday, October 28, 2022

[7:30-9:00] Session VI: Prognostic and Predictive Markers

Prashant Kapoor, Efstathios Kastritis, [Chairs]

Models-Risk Stratification of Asymptomatic WM

Romanos Sklavenitis-Pistofidis, Dana Farber Cancer Institute, USA

Predictors of Short Survival in WM

Prashant Kapoor, Mayo Clinic, USA

Impact of 6q on WM clinical outcomes

Ramon Garcia-Sanz, University of Salamanca, Spain

Clinical Response Predictors for BTK-I

Jithra Abeykoon, Mayo Clinic, USA

CXCR4 subtype and clonality impact ibrutinib response

Joshua Gustine, Dana Farber Cancer Institute, USA

Prognostic Impact of MYD88 L265P by ddPCR

Carlos Fernandez de Larrea, Hospital Clinic Barcelona, Spain

 

[9:00-9:30] Morning Break

  

[9:30-11:30] Session VII: Chemoimmunotherapy

Veronique Leblond, Luigi Qiu [Chairs]       

B-RCD vs. RCD Randomized Trial in WM

Pierre Morel, Centre Hospitalier de Lens, France

RCD vs BCD Randomized Trial

Luigi Qiu, National Clinical Research Center for Blood Diseases, China

Bendamustine/Rituximab: Dose Intensity and Patient Outcomes

Suzanne Arulogun, UC London Hospitals NHS, UK

FILO Bendamustine Rituximab

Veronique Leblond, Hôpital Pitié Salpêtrière, France

HOVON 124: Ixazomib, Dex., Rituximab in Previously Treated WM

M.J. Kersten, University of Amsterdam, Netherlands

STIL Maintenance Rituximab

Mathias Rummel, University of Giessen, Germany

BRB: Bendamustine, Rituximab, Bortezomib Study: Fondazione Italiana Linfomi Study

Giulia Benevolo, University of Torino, Italy

 

[11:30-12:30] LUNCH

 

[12:30-14:15] Session VIII: BTK-Inhibitors I

Judith Trotman, Meletios Dimopoulos [Chairs]

Long Term Follow-Up of Ibrutinib Monotherapy in Previously Treated WM

Steven Treon, Dana Farber Cancer Institute, USA

INNOVATE C/Update

Meletios Dimopoulos, University of Athens, Greece

Long Term Follow-Up of Ibrutinib Monotherapy in Frontline WM

Jorge Castillo, Dana Farber Cancer Institute, USA

Long Term Follow-up-INNOVATE A/B

Christian Buske, University Hospital Ulm, Germany

Real World Experiences with Ibrutinib-US experience

Jithra Abeykoon, Mayo Clinic, USA

Real World Experiences with Ibrutinib-UK experience

Shirley D’Sa, UC London Hospitals NHS, UK

Real World Data on CIT and BTK-inhibitors: WHIMSICAL Study

Ibrahim Tohidi-Esfahani, University of Sydney, Australia

 

[14:15-15:30] Session IX: BTK-Inhibitors II

Alessandra Tedeschi, Constantine Tam, [Chairs]

Long Term Follow-up-Acalabrutinib Phase II

Roger Owen, Leeds Hospital NHS Trust, UK

Long Term Follow-Up Zanubrutinib-Phase II

Judith Trotman, University of Sydney, Australia

Phase II Zanubrutinib in relapsed/refractory WM: Chinese experience

Luigi Qui, National Clinical Research Center for Blood Diseases, China

Long Term Follow-up-ASPEN

Constantine Tam, Peter MacCallum Cancer Centre, Australia

Long Term Follow-Up of Zanubrutinib in MYD88 WT WM

Meletios Dimopoulos, University of Athens, Greece

 

 

[15:30-16:00] Afternoon Break

 

 

[16:00-16:30] Keynote Lectures

Benda or BTK-I for frontline WM treatment: Insights from CLL SEQUOIA Trial

Keynote Speaker: Constantine Tam, Peter MacCallum Cancer Centre, Australia

Mechanistic Insights into Adverse Events underlying BTK-inhibitors

Keynote Speaker: C.I. Edvard Smith, Karolinska Institut, Sweden

 

[16:30-17:45] Session: X: Management of BTK-inhibitor exposed patients

Shayna Sarosiek, Carlos De Larrea [Chairs]

Dose reduction of ibrutinib and impact on treatment course

Shayna Sarosiek, Dana Farber Cancer Institute, USA

Zanubrutinib in patient’s intolerant to ibrutinib/acalabrutinib

Mazyar Shadman, Fred Hutchinson Cancer Res Center, USA

Venetoclax in Previously Treated WM incl. BTK-inhibitor exposed patients

Jorge Castillo, Dana Farber Cancer Institute, USA

Pirotbrutinib in Previously Treated WM Patients with Covalent BTK-inhibitor

Michael Wang, MD Anderson, USA

MK-1026 Dose Expansion Study in B-cell malignancies incl WM

Deborah Stephens, University of Utah, Huntsman Cancer Institute, USA

 

 

 

[17:45-18:30] Special Topics Lectures

Clinical Characteristics and Outcomes with Cryoglobulinemia in WM

Speaker: Shirley D’Sa, UC London Hospitals NHS, UK

Clinical Characteristics and Outcomes with Cold Agglutinins in WM

Speaker: Josephine Vos, University of Amsterdam, Netherlands

Management of Amyloidosis in WM Patients

Speaker: Giampaolo Merlini, University of Pavia, Italy

 

[19:30] Departures for Faculty Dinner Reception

Saturday, October 29, 2022

[7:30-10:15] Session XI: Great Debates in WM

Eva Kimby, Jesus San Miguel [Chairs]

 

[7:30-8:00] Great Debate I

Should we treat smoldering WM? -No

Prashant Kapoor, Mayo Clinic, USA

Should we treat smoldering WM? -Yes

Irene Ghobrial, Dana Farber Cancer Institute

 

[8:00-8:30] Great Debate II

Should BTK-I or Benda-R be the standard frontline induction regimen? -for Benda-R

Christian Buske, University Hospital Ulm, Germany

Should BTK-I or Benda-R be the standard frontline induction regimen? -for BTK-I

Meletios Dimopoulos, University of Athens, Greece

 

[8:30-9:15] Great Debate III

Does the choice of BTK-inhibitor matter? -for Ibrutinib

Ranjana Advani, Stanford University Medical Center, USA

Does the choice of BTK-inhibitor matter? -for Acalabrutinib

Roger Owen, Leeds Hospital NHS Trust, UK

Does the choice of BTK-inhibitor matter? -for Zanubrutinib

Judith Trotman, University of Sydney, Australia

 

[9:15-9:45] Great Debate IV

Managing the ibrutinib intolerant patient: Dose reduce or switch to another BTK-inhibitor? -Dose reduce

M Lia Palomba, Memorial Sloan Kettering Cancer Center, USA

Managing the ibrutinib intolerant patient: Dose reduce or switch to another BTK-inhibitor? -Switch

Alexandra Tedeschi, Niguarda Hopital, Italy

 

[9:45-10:15] Great Debate V

What should be the end point of therapy in WM? -Disease control should be the endpoint of therapy

Stathis Kastritis, University of Athens, Greece

What should be the end point of therapy in WM? -CR should be the endpoint of therapy

Jorge Castillo, Dana Farber Cancer Institute, USA

 

[10:15-10:45] Morning Break

 

[10:45-11:45] Session XII: Novel Treatment Approaches to WM-Clinical I

Sheeba Thomas, Moshe Gatt [Chairs]

Venetoclax in combination with ibrutinib for WM

Jorge Castillo, Dana Farber Cancer Institute, USA

Targeting mutated CXCR4 in WM

Steven Treon, Dana Farber Cancer Institute, USA

Obinutuzumab and Idelalisib in WM

Veronique Leblond, Hôpital Pitié Salpêtrière, France

Acalabrutinib and Rituximab for WM and IGM RD PN

Shayna Sarosiek, Dana Farber Cancer Institute, USA

 

 

[11:45-12:45] Session XIII: Novel Treatment Approaches to WM-Clinical II

Jorge Castillo, Stephen Ansell [Chairs]

Tirabrutinib in Treatment Naïve and Prev Treated WM-Phase II

Koji Izutsu, National Cancer Center Hospital, Japan

Phase II study of Orelabrutinib in relapsed/refractory WM

Xinxin Cao, Peking Union Medical College, China

Clinical Activity of IRAK4 Inhibitor CA-4948 in NHL, incl. WM

Reinhard Von Roemeling, Curis Pharmaceuticals, USA

 

 

[12:45-13:45] LUNCH

 

 

[13:45-14:30] Session XIV: Novel Treatment Approaches to WM-Clinical III

Merav Leiba, Shirley D’Sa [Chairs]

Bispecifics in WM-CD3XCD20 RGN1979

Stephen Ansell, Mayo Clinic, USA

Phase II Study of Loncastuximab in WM

Shayna Sarosiek, Dana Farber Cancer Institute, USA

Idiotype DNA Vaccine Therapy for WM

Sheeba Thomas, MD Anderson, USA

 

[14:30-15:00] Keynote Lectures

Bispecifics and Conjugated Antibodies: MM Experience

Keynote Speaker: Kenneth C. Anderson, Dana Farber Cancer Institute, USA

Bringing CART to WM: Which One?

Keynote Speaker: Nikhil Munshi, Dana Farber Cancer Institute, USA

 

[15:00-15:30] Afternoon Break

 

 

[15:30] Keynote Lectures

Challenges of COVID in WM Patient Care

Keynote Speaker: Meletios Dimopoulos, University of Athens, Greece

 

[16:00-17:15] Session XV: COVID and WM

Ramon Garcia Sanz, Andrew Branagan [Chairs]

Responses to COVID vaccination in WM and MM Patients

Andrew Branagan, Massachusetts General Hospital, USA

Responses to COVID vaccination (initial and booster dose) in patients with plasma cell neoplasms

Evangelos Terpos, University of Athens, Greece

GETH-TC Study on Serological responses to initial vaccination and booster in heme patients with /without prior COVID19

Ramon Garcia-Sanz, University of Salamanca, Spain

Efficacy of BNT162b2 in WM and FLL -Australian Experience

Judith Trotman, University of Sydney, Australia

Impact of Booster Vaccination on SARS-COV-2 Antibody Levels in Blood CA Patients incl. WM

Lee Greenberger, Leukemia Lymphoma Society (LLS), USA

 

 

[19:30] Dinner Reception & Closing Ceremonies

Presentation of Peter S. Bing Humanitarian Awards

Presentation of Jan Gosta Waldenstrom Awards

Sunday, October 30, 2022

[9 :00-10 :00] Session XVI: Plenary

Veronique Leblond, Jésus San Miguel [Chairs]

Presentation 1

TBD

Presentation 2

TBD

Presentation 3

TBD

Presentation 4

TBD

 

[10:00-10:30] Morning Break

 

[10:30-12:30] Panel Discussions: WM Management I

Organizers: Christian Buske, Jorge Castillo, Judith Trotman

WM Consensus Panel I Report

IWWM-11 Recommendation for Treatment Approach in WM-Frontline

 

Organizers: Efstathios Kastritis, Shirley D'SA, Jeffrey Matous

WM Consensus Panel II Report

IWWM-11 Recommendation for Treatment Approach in WM-Relapsed/Refractory

 

Organizers: Ramon Garcia-Sanz, Marzia Varettoni, Zachary Hunter

WM Consensus Panel III Report

IWWM-11 Recommendation for Molecular Diagnostic Workup in WM

 

Organizers: Steve Treon, Roger Owen, Alessandra Tedeschi

WM Consensus Panel IV Report

Response Criteria for WM

 

[12:30-13:30] LUNCH

 

[13:30-15:00] Panel Discussions: WM Management II

Organizers: Meletios Dimopoulos, Veronique LeBlond, Andrew Branagan

WM Consensus Panel V Report

COVID Prophylaxis and Management in WM

 

Organizers: Monique Minnema, Shayna Sarosiek, Giampaolo Merlini

WM Consensus Panel VI Report

Management of WM-related Amyloidosis

 

Organizers: MJ Kersten, Prashant Kapoor, Constantine Tam

WM Consensus Panel VII Report

Priorities for Novel Clinical Trials

The Bing Center

ing Center for Waldenstrom's Macroglobulinemia
Dana Farber Cancer Institute
Harvard Medical School

Contact

Christopher Patterson
Secretariat

Address

450 Brookline Avenue

Mayer 548

Boston, MA 02215

p +1 617 632 6285

f +1 617 632 4862

Newsletter

Enter your email address for news about the 11th IWWM.